Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
PRLD
vs
S&P 500
PRLD
S&P 500
Over the past 12 months, PRLD has significantly outperformed S&P 500, delivering a return of +165% compared to S&P 500's +16% growth.
Stocks Performance
PRLD vs S&P 500
Performance Gap
PRLD vs S&P 500
Performance By Year
PRLD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Prelude Therapeutics Inc
Glance View
Prelude Therapeutics is a clinical-stage drug developer focused on cancer. It designs small-molecule medicines that aim to block the specific proteins and pathways that help certain tumors grow, especially in cancers with known genetic drivers. Its work starts in the lab and moves through clinical testing before any drug can be sold broadly. The company does not sell a large portfolio of marketed products. Its business is based on advancing its own drug candidates and, when possible, making money through research collaborations, licensing, or future commercial sales if a medicine reaches approval. For now, its main “customers” are really the doctors, hospitals, and patients that would use its drugs later, along with potential pharmaceutical partners that may help fund development. What makes Prelude’s model different is that it is concentrated on precision oncology rather than broad cancer treatment. It tries to find narrow patient groups whose tumors depend on a specific target, which can make a drug more useful in the right setting but also raises the scientific and regulatory risk. In simple terms, Prelude is a research-heavy biotech trying to turn targeted cancer science into approved medicines.